Патогенетические основы синдрома раздраженного кишечника у пациентов, перенесших новую коронавирусную инфекцию (COVID-19): ОБЗОРЫ

Андрей Васильевич  Налетов; Анатолий Ильич  Хавкин; Полина Игоревна  Налетова; Яна Анатольевна  Соцкая

doi:10.56871/

Pathogenetic basis of irritable bowel syndrome in patients with new coronavirus infection (COVID-19)

REVIEWS

Andrew V. Nalyotov M. Gorky Donetsk State Medical University https://orcid.org/0000-0002-4733-3262
Anatoly I. Khavkin Research Clinical Institute of Childhood, Ministry of Health of the Moscow Region; Belgorod State National Research University https://orcid.org/0000-0001-7308-7280
Polina I. Nalyotova Donetsk Central City Clinical Hospital No. 1 https://orcid.org/0009-0001-9923-6974
Yana A. Sotskaya Lugansk State Medical University named after St. Luke https://orcid.org/0000-0003-1729-8352

Keywords:

irritable bowel syndrome COVID-19 gastrointestinal complaints postcovoid syndrome синдром раздраженного кишечника COVID-19 гастроинтестинальные жалобы постковидный синдром

Abstract

The clinical manifestations of COVID-19 can range from asymptomatic to severe or fatal cases.
Most patients recover completely, but a significant number of patients develop post-covid syndrome within a few weeks or even months after the disappearance of acute manifestations of infection, which is characterized by the presence of clinical symptoms from different organs and systems. One of the manifestations of COVID-19 and post-COVID syndrome is complaints from the gastrointestinal tract, which, according to the results of clinical studies, are registered in 10–60% of patients. The article presents current data on the prevalence of irritable bowel syndrome in patients of different ages who have had COVID-19. Potential mechanisms that may link COVID-19 to the development of irritable bowel syndrome have been identified. The growing amount of evidence of the role of the new coronavirus infection in the formation of gastrointestinal symptoms underscores the need for further research on the long-term effects of SARS-Co V-2 infection, not only in relation to respiratory pathology, but also in relation to the state of the gastrointestinal tract, including the occurrence of irritable bowel syndrome.

Author Biographies

Andrew V. Nalyotov, M. Gorky Donetsk State Medical University

Dr. Sci. (Med.), Professor, Head of the Department of Pediatrics № 2

Anatoly I. Khavkin, Research Clinical Institute of Childhood, Ministry of Health of the Moscow Region; Belgorod State National Research University

Dr. Sci. (Med.), Professor, Head of the Moscow Regional Center of Pediatric Gastroenterology and Hepatology of the Research Clinical Institute of Childhood, Ministry of Health of the Moscow Region; Professor, Department of Pediatrics, Medical Institute, Belgorod National Research University

Polina I. Nalyotova, Donetsk Central City Clinical Hospital No. 1

infectiologist of the Donetsk Central City Clinical Hospital No. 1

Yana A. Sotskaya, Lugansk State Medical University named after St. Luke

Dr. Sci. (Med.), Professor, Head of the Department of Infectious Diseases and Epidemiology named after V.M. Frolov

References

1. Джулай Г.С., Джулай Т.Е. Клинико-патогенетические особенности диарейного синдрома, ассоциированного с течением COVID-19. Экспериментальная и клиническая гастроэнтерология. 2022;205(9):276–283. https://doi.org/10.31146/1682-8658-ecg-205-9-276-283.

2. Налетов А.В., Шапченко Т.И., Гуз Н.П. Некоторые клинико-патогенетические аспекты синдрома раздраженного кишечника у пациентов, перенесших COVID-19. Экспериментальная и клиническая гастроэнтерология. 2023;215(7):60–65. https://doi.org/10.31146/1682-8658-ecg-215-7-60-65.

3. Crook H., Raza S., Nowell J. et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:1648. https://doi.org/10.1136/bmj.n1648.

4. Гриневич В.Б., Лазебник Л.Б., Кравчук Ю.А. и др. Поражения органов пищеварения при постковидном синдроме. Клинические рекомендации. Экспериментальная и клиническая гастроэнтерология. 2022;208(12):4–68. https://doi.org/10.31146/1682-8658-ecg-208-12-4-68.

5. Oronsky B., Larson C., Hammond T.C. et al. A Review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64:66–74. https://doi.org/10.1007/s12016-021-08848-3.

6. Carfì A., Bernabei R., Landi F. Gemelli against COVID-19 post-acute care study group. persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. https://doi.org/10.1001/jama.2020.12603.

7. Taribagil P., Creer D., Tahir H. “Long COVID” syndrome. BMJ Case Rep. 2021;14(4):e241485. https://doi.org/10.1136/bcr-2020-241485.

8. Налетов А.В., Масюта Д.И., Чалая Л.Ф. Патогенетические основы синдрома раздраженного кишечника у пациентов, перенесших COVID-19. Мать и Дитя в Кузбассе. 2021;4(87):12-16.

9. Marasco G., Maida M., Cremon G. et al. Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome. Aliment Pharmacol Ther. 2023;58(1):6–15. https://doi.org/10.1111/apt.17513.

10. Settanni C.R., Ianiro G., Ponziani F.R. et al. COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World J Gastroenterol. 2021;27(43):7433–7445. https://doi.org/10.3748/wjg.v27.i43.7433.

11. Austhof E., Bell M. L., Riddle M. S. et al. Persisting gastrointestinal symptoms and post-infectious IBS following SARS-Co V-2 infection: results from Arizona Co VHORT. Epidemol Infect. 2022;150:e136. https://doi.org/10.1017/S0950268822001200.

12. Marasco G., Cremon C., Barbaro M.R. et al. Post COVID-19 irritable bowel syndrome. Gut. 2022;72(3):328483. https://doi.org/10.1136/gutjnl-2022-328483.

13. Silva J.T.C., da Fonseca Neto O.C.L. Post-COVID-19 irritable bowel syndrome: an integrative review. Rev Col Bras Cir. 2023;50:e20233618. https://doi.org/10.1590/0100-6991e-20233618-en.

14. Wang Z., Peng Y., Chen M. et al. The prevalence of irritable bowel syndrome after severe acute respiratory syndrome coronavirus 2 infection and their association: a systematic review and meta-analysis of observational studies. J Clin Med. 2023;12(5):1865. https://doi.org/10.3390/jcm12051865.

15. Новикова В.П., Полунина А.В., Баннова С.Л. и др. Состояние желудочно-кишечного тракта у детей при новой коронавирусной инфекции и в постковидный период. Роль синбиотика в коррекции клинических симптомов, кишечной микробиоты и проницаемости кишечной стенки. РМЖ. Мать и дитя. 2023;6(3):283–289. https://doi.org/10.32364/2618-8430-2023-6-3-10.

16. Новикова В.П., Полунина А.В., Баннова С.Л. и др. Эффективность применения синбиотика Максилак® при новой коронавирусной инфекции после антибактериальной терапии. Педиатрия. Consilium Medicum. 2024;(2):167–172. https://doi.org/10.26442/26586630.2024.2.202935.

17. Wechsler J.B., Berken J.A., Keeley K. et al. Somatic, emotional, and gastrointestinal symptom severity are increased among children and adolescents with COVID-19. Neurogastroenterol Motil. 2024;36(11):e14909. https://doi.org/10.1111/nmo.14909.

18. Shih A.R., Misdraji J. COVID-19: Gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2023;132:39–55. https://doi.org/10.1016/j.humpath.2022.07.006.

19. Косенкова Т.В., Тимченко В.Н., Новикова В.П. и др. Коронавирусная инфекция и COVID-19 у детей. Часть 2. Клинические особенности COVID-19 у детей: легочные и внелегочные проявления, осложнения, в том числе мультисистемный воспалительный синдром. Children`s Medicine of the North-West. 2025;13(1):16–38.

20. Харитонова Л.А., Османов И. М., Плоскирева А.А. и др. Поражения органов пищеварения при COVID-19 у детей. Экспериментальная и клиническая гастроэнтерология. 2021;185(1):53–66. https://doi.org/10.31146/1682-8658-ecg-185-1-53-66.

21. Налетов А.В., Масюта Д.И., Гуз Н.П. Особенности клинических проявлений синдрома раздраженного кишечника у детей, перенесших COVID-19. Children’s Medicine of the North-West. 2021;9(2):45–49.

22. Foster H.M.E., Ho F.K., Mair F.S. et al. The association between a lifestyle score, socioeconomic status, and COVID-19 outcomes within the UK Biobank cohort. BMC Infect Dis. 2022;22(1):273. https://doi.org/10.1186/s12879-022-07132-9.

23. Johnson A.G., Amin A.B., Ali A.R. et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence — 25 U.S. Jurisdictions, April 4 — December 25, 2021. Morb Mortal Wkly Rep. 2022;71(4):132–138. https://doi.org/10.15585/mmwr.mm7104e2.

24. Новикова В.П., Полунина А.В. Состав кишечной микробиоты при COVID инфекции (научный обзор). Профилактическая и клиническая медицина. 2020;4(77): 81–86.

25. Scarpellini E., Tack J. Post-COVID-19 gastro-intestinal disturbances. Rev Recent Clin Trials 2023;18(1):34–40. https://doi.org/10.2174/1574887118666221201104833.

26. Полунина А.В., Новикова В.П., Баннова С.Л. и др. К вопросу о патогенезе постковидных функциональных расстройств желудочно-кишечного тракта у детей. Экспериментальная и клиническая гастроэнтерология. 2025;(2):108–113. https://doi.org/10.31146/1682-8658-ecg-234-2-108-113.

27. Oshima T. Siah K.T.H., Yoshimoto T. et al. Impacts of the COVID-19 pandemic on functional dyspepsia and IBS: a population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–1827. https://doi.org/10.1111/jgh.15346.

28. Porcari S., Ingrosso M.R., Maida M. et al. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis. Gut. 2024;73(9):1431–1440. https://doi.org/10.1136/gutjnl-2023-331835.

29. Noviello D., Costantino A., Muscatello A. et al. Functional gastrointestinal and somatoform symptoms four month after SARS-Co V-2 infection: a controlled cohort study. Neurogastroenterol Motil. 2021;34(2):e14187. https://doi.org/10.1111/nmo.14187.

30. Effenberger M., Grabherr F., Mayr L. et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69(8):1543–1544. https://doi.org/10.1136/gutjnl-2020-321388.

31. Batiha G.E., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Pathophysiology of Post-COVID syndromes: A new perspective. Virol J. 2022;19:158. https://doi.org/10.1186/s12985-022-01891-2.

32. Полунина А.В., Новикова В.П., Блинов А.Е. и соавт. Динамика уровня зонулина в стуле при инфекции COVID-19 и в постковидный период у детей. Инфекционные болезни. 2022;20(3):35–40. https://doi.org/10.20953/1729-9225-2022-3-35-40.

33. Gu S., Chen Y., Wu Z. et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–2678. https://doi.org/10.1093/cid/ciaa709.

34. Liu Q., Mak J.W.Y., Su Q. et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544–552. https://doi.org/10.1136/gutjnl-2021-325989.

35. Zuo T., Zhang F., Lui G.C.Y. et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944–955.e8. https://doi.org/10.1053/j.gastro.2020.05.048.

36. Rogers J.P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. https://doi.org/10.1016/S2215-0366(20)30203-0.

37. Janiri D., Kotzalidis G. D., Giuseppin G. et al. Psychological distress after COVID-19 recovery: reciprocal effects with temperament and emotional dysregulation. An exploratory study of patients over 60 years of age assessed in a post-acute care service. Front Psychiatry. 2020;11:590135. https://doi.org/10.3389/fpsyt.2020.590135.

38. Shigemura J., Ursano R.J., Morganstein J.C., Kurosawa M., Benedek D.M. Public responses to the novel 2019 coronavirus (2019-n Co V) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281–282. https://doi.org/10.1111/pcn.12988.

39. Ивашкин В.Т., Абдулхаков Р.А., Бакулин И.Г. и др. Пандемия COVID-19 и СРК. Результаты Всероссийской наблюдательной неинтервенционной программы изучения эффективности препарата Колофорт® в условиях реальной клинической практики у пациентов с синдромом раздраженного кишечника после перенесенной новой коронавирусной инфекции (ВЕСНА). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(5):41–53. https://doi.org/10.22416/1382-4376-2023-33-5-41-5.

40. Kamp K.J., Levy R.L., Munson S.A., Heitkemper M.M. Impact of COVID-19 on individuals with irritable bowel syndrome and comorbid anxiety and/or depression. J Clin Gastroenterol. 2022;56(2):e149–e152. https://doi.org/10.1097/MCG.0000000000001515.

41. Vodnar D.C., Mitrea L., Teleky B.E. et al. Coronavirus disease (COVID-19) caused by (SARS-Co V-2) infections: A real challenge for human gut microbiota. Front Cell Infect Microbiol. 2020;10:575559. https://doi.org/10.3389/fcimb.2020.575559.

42. Chan W.W., Grover M. The COVID-19 pandemic and post-infection irritable bowel syndrome: what lies ahead for gastroenterologists. Clin Gastroenterol Hepatol. 2022;20(10):2195–2197. https://doi.org/10.1016/j.cgh.2022.05.044.

43. Sabate J-M., Deutsch D., Melchior C. et al. COVID-19 pandemic and lockdown stress consequences in people with and without irritable bowel syndrome. Ethics Med Public Health. 2021;18:100660. https://doi.org/10.1016/j.jemep.2021.100660.

44. Liu X., Li D., Gao W. et al. Shared genetic architecture between COVID-19 and irritable bowel syndrome: a large-scale genome-wide cross-trait analysis. Front Immunol. 2024:15:1442693. https://doi.org/10.3389/fimmu.2024.1442693.

Pathogenetic basis of irritable bowel syndrome in patients with new coronavirus infection (COVID-19): REVIEWS. (2026). Children’s Medicine of the North-West, 13(4), 60-71. https://doi.org/10.56871/

Download Citation

How to Cite

Pathogenetic basis of irritable bowel syndrome in patients with new coronavirus infection (COVID-19): REVIEWS. (2026). Children’s Medicine of the North-West, 13(4), 60-71. https://doi.org/10.56871/

Download Citation